Acquisition strengthens separation science support

A strategic move which has brought Reach Separations, under the umbrella of medicines development partner CatSci, aims to offer end-to-end separation science support from discovery to manufacture. The acquisition was supported by Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments.

Headquartered at Biocity Nottingham (UK) and with laboratories in both the UK and France, Reach Separations specialises in chromatography for the analysis and purification of chiral and achiral therapeutics. A differentiated analytical offering, along with its highly skilled workforce, enables the company to deliver purification projects from discovery chromatography through to large scale SFC (Supercritical Fluid Chromatography) for chiral purification and impurity isolation. The move is expected to provide high quality analysis for small molecules, oligonucleotides and other complex synthetic medicines.

This acquisition marks a significant milestone in CatSci’s growth strategy as the company continues to enhance its CMC (Chemistry, Manufacturing and Controls) capabilities to add strategic value to their partnerships with customers.

Dr Ross Burn, CEO at CatSci, commented: “We are excited to welcome Reach Separations into the CatSci Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.’’

Peter Ridgway, Business Development Director at Reach Separations, added: “Becoming part of the CatSci Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces.”

James Mitchell, Partner at Keensight Capital, concluded: “We are delighted that Reach Separations has joined the CatSci Group and look forward to continuing to support the company in this next phase of their growth. Having identified CatSci as a company with exceptional potential, unique positioning and strong expertise in the small molecule R&D, we believe that the addition of Reach’s differentiated offering, analytical capabilities and strong employee base will ensure that the combined company is well positioned for future growth in this space.”

More information online